Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | WRN | Q14191 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10105716 | 1.00 | ALDH1A1 (0.33) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL12261667 | 0.86 | ALDH1A1 (0.32) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL10168507 | 0.85 | PTGS1 (0.31) | — | |
| SCHEMBL181744 | 0.84 | ALDH1A1 (0.34) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL45664 | 0.84 | ALDH1A1 (0.34) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL12680320 | 0.81 | ALDH1A1 (0.34) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL9441056 | 0.81 | GSK3B (0.37) | GSK3AGSK3BLMNA | |
| SCHEMBL10285978 | 0.80 | — | — | |
| SCHEMBL20057032 | 0.80 | MGLL (0.41) | — | |
| SCHEMBL15991683 | 0.79 | ALDH1A1 (0.31) | ALDH1A1CYP1A2HPGDCYP2C19BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210252160-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS | IL-2RX | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252160-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS | TNFRSF9, EGFR, NGFR | ALDH1A1 4499/4885CYP1A2 4745/4885HPGD 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.